Abrdn Life Sciences Investors (HQL) Fundamental Analysis: Revenue, Earnings & Valuation

2.61 / 10

Underperform

Fundamental analysis rates the company as Underperform (2.6/10). Inventory turnover and gross profit margin are strengths, yet current‑asset ratio, quick ratio and negative return on assets drag performance. Diluted EPS growth is modest, leading to an overall low fundamental score of 2.61.

Analysis Checks(7/9)

Inventory turnover ratio

Value103.94

Score2/3

Weight11.84%

1M Return1.58%

Gross profit margin (%)

Value41.83

Score2/3

Weight12.09%

1M Return1.58%

Quick ratio

Value2.28

Score2/3

Weight11.82%

1M Return1.58%

Rate of return on total assets (%)

Value-10.79

Score2/3

Weight11.97%

1M Return1.61%

Fixed assets turnover ratio

Value9306.28

Score2/3

Weight9.63%

1M Return1.28%

Annualized return on total assets (%)

Value-10.79

Score2/3

Weight11.97%

1M Return1.61%

Diluted earnings per share (YoY growth rate %)

Value32.21

Score0/3

Weight6.79%

1M Return0.93%

Current assets / Total assets (%)

Value47.20

Score1/3

Weight11.57%

1M Return1.50%

Current ratio

Value3.94

Score2/3

Weight12.32%

1M Return1.60%

Is HQL fundamentally strong?

HQL scores 2.61/10 on fundamentals and holds a Premium valuation at present. Backed by its 17.59% ROE, 4415.74% net margin, 5.82 P/E ratio, 0.97 P/B ratio, and 0.00% earnings growth, these metrics solidify its Underperform investment rating.